MICHAELA DUQUENOY: Open Payments
NPI 1659085082 · PAWTUCKET, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$621 in 28 payments from 13 companies in 2025. Trend: 2023 $105 · 2024 $424 · 2025 $621
Food & beverage: $621
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $179 |
| ABBVIE INC. | 4 | $103 |
| Ardelyx, Inc. | 2 | $53 |
| Amgen Inc. | 2 | $51 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $37 |
| Lilly USA, LLC | 2 | $34 |
| Lundbeck LLC | 1 | $27 |
| Boston Scientific Corporation | 1 | $22 |
| Novo Nordisk Inc | 1 | $18 |
Products named: FARXIGA, UBRELVY, REXULTI, IBSRELA, Kerendia, KISUNLA, EVENITY, LINZESS.
Industry payments across RI — which companies pay providers there.
